Credit Suisse Maintains Outperform on Amgen, Lowers Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
Credit Suisse analyst Trung Huynh has maintained an Outperform rating on Amgen (NASDAQ:AMGN) but lowered the price target from $220 to $200.

July 12, 2023 | 11:16 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Amgen's price target has been lowered from $220 to $200 by Credit Suisse, though the Outperform rating is maintained.
The lowering of the price target by Credit Suisse could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained Outperform rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100